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Synopsis 18 
Background Clustered Regularly Interspaced Short Palindromic Repeats 19 
(CRISPR) and their associated cas genes are sequence specific DNA 20 
nuclease systems found in bacteria and archaea. CRISPR/Cas systems use 21 
RNA transcripts of previously acquired DNA (spacers) to target invading 22 
genetic elements with the same sequence, including plasmids. In this 23 
research we studied the relationship between CRISPR/Cas systems and 24 
multi-drug resistance in Escherichia coli. 25 
Methods The presence of Type I-E and Type I-F CRISPR systems were 26 
investigated among 82 antimicrobial susceptible and 96 MDR clinical E. coli 27 
isolates by PCR and DNA sequencing. Phylogrouping and MLST were 28 
performed to determine relatedness of isolates. RT-PCR was performed to 29 
ascertain the expression of associated cas genes. 30 
Results Type I-F CRISPR was associated with the B2 phylogroup and was 31 
significantly overrepresented in the susceptible group (22.0%) compared to 32 
the MDR group (2.1%). The majority of CRISPR I-F containing isolates had 33 
spacer sequences that matched IncF and IncI plasmids. RT-PCR 34 
demonstrated that Type I-F cas genes were expressed and therefore 35 
potentially functional. 36 
Conclusion The CRISPR I-F system is more likely to be found in 37 
antimicrobial susceptible E. coli. Given that the Type I-F system is expressed 38 
in wild-type isolates, we suggest that this difference could be due to the 39 
CRISPR system potentially interfering with the acquisition of antimicrobial 40 
resistance plasmids, maintaining susceptibility in these isolates.   41 
Introduction	42 
Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) loci 43 
were first observed over 20 years ago and have since been found in the 44 
genomes of many bacteria and archaea.1 Along with their associated Cas 45 
proteins, the system collectively known as CRISPR/Cas, has been described 46 
as providing adaptive immunity for bacteria, targeting potentially deleterious or 47 
costly invading DNA such as phages or plasmids. CRISPR loci consist of 48 
short 21 to 47 base pair (bp) repeats separated by similarly sized non-49 
repeating sequences called spacers.2 The repeat arrays are often, but not 50 
always, associated with cas genes which encode the proteins involved in the 51 
function of the CRISPR/Cas system. The CRISPR/Cas system leads to the 52 
enzymatic cleavage of double stranded DNA in precise sites determined by 53 
the sequence of the spacer.3 The process can be divided into two stages; 54 
acquisition and interference. In the acquisition stage, Cas1 and Cas2 proteins 55 
scan invading DNA for a short 3-6 bp motif (called the Protospacer Adjacent 56 
Motif or PAM). Sequences immediately next to the PAM are processed and 57 
integrated into the CRISPR array; these spacers are then transcribed and 58 
processed into CRISPR RNA (crRNA), and this RNA is used in the 59 
interference stage to guide the Cas nuclease complex to cleave 60 
complementary DNA.1  61 
With recent attention focused on the genetic engineering potential of 62 
CRISPR/Cas, its natural role has received less attention. The existence of an 63 
adaptive immune system that rids bacteria of mobile genetic elements 64 
(MGEs) is paradoxical in terms of survival. Indeed, the ubiquitous distribution 65 
of mobile genetic elements among bacterial species suggests that CRISPR 66 
systems are not always functional, or that they may have other roles such as 67 
the regulation of gene expression4 and/or as yet undiscovered roles. In some 68 
environments, host bacteria clearly benefit from plasmid-encoded traits such 69 
as antimicrobial resistance and possession of CRISPR systems to rid the cell 70 
of such as plasmids is likely to be rapidly selected against. The assumption 71 
that CRISPR functions as an immune system has been called into question in 72 
E. coli.5 We set out to explore this paradox. 73 
Two subtypes of CRISPR are known in E. coli, Type I-E and Type I-F.6 74 
In both types, the genes are clustered and closely flanked by two repeat 75 
arrays each; CRISPR1 and CRISPR2 for Type I-E, and CRISPR3 and 76 
CRISPR4 for I-F. Both systems are similar but the Type I-E system has 8 77 
genes whereas Type I-F has 6.7 The functionality of the Type I-E system has 78 
been brought in to question due to the finding that Type I-E cas genes are 79 
repressed by the global regulator H-NS under laboratory conditions.8 80 
Conversely, Type I-F cas genes have been shown to be constitutively 81 
expressed.9 Due to the spacer content of the two systems, it has previously 82 
been hypothesized that the Type I-E system may be specialized in targeting 83 
bacteriophages whereas the Type I-F system is more associated with 84 
plasmids.6  85 
In this study, we examine the relationship between CRISPR and 86 
antimicrobial resistance plasmids in E. coli by comparing the prevalence of 87 
CRISPR Type I-E and I-F systems in antimicrobial susceptible and resistant 88 
isolates. Additionally, by investigating expression of Type I-F cas genes, we 89 
aim to gain an insight into the activity of these systems and potential 90 
interference against natural antimicrobial resistance plasmids. 91 
Methods 92 
E. coli isolates and antimicrobial susceptibility testing 93 
A total of 178 clinical E. coli isolates, derived from three sources, were 94 
available for the study. Isolates were split into two groups; MDR10 comprising 95 
96 isolates and fully susceptible, comprising 82 isolates, based on known 96 
susceptibility testing results to 10 or more antimicrobials. The three sources 97 
comprised; 90 (33 susceptible and 57 MDR) recent urine isolates from the 98 
Royal Free Hospital (RFH), London collected between 2014 and 2015; 39 99 
MDR isolates from Jaroden Hospital and Alexandria University in Egypt 100 
between 2009 and 2011, and 49 susceptible community urine isolates from 101 
South West of England collected between 2005-2006. Egyptian isolates were 102 
chosen on the basis of resistance to 3rd generation cephalosporins and 103 
carbapenems. RFH isolates were picked at random from available fully 104 
susceptible or MDR E. coli isolates from the urine bench. The isolates from 105 
South West England represented the first 50 fully susceptible isolates in a 106 
larger collection forming part of another study.  All isolates were subjected to 107 
additional susceptibility testing to antimicrobials commonly associated with 108 
plasmid-acquired genes (ampicillin, gentamicin, tetracycline, ciprofloxacin, 109 
chloramphenicol and sulfamethoxazole) using the EUCAST disc diffusion 110 
method. All isolates are listed in Table S1. 111 
PCR and DNA sequencing 112 
PCR was used to screen for four known CRISPR arrays with primers from 113 
Touchon et al.5 (listed in Table 1). PCR reactions were prepared using 114 
HotStar Taq Mastermix (Qiagen) according to manufacturer’s instructions 115 
(12.5 µl MasterMix, 0.2-1 mM of each primer and 20-100 ng of DNA up to 25 116 
µl total volume). PCR products were visualized in agarose/ethidium bromide 117 
gels under UV light. The presence of CRISPR3 and CRISPR4 arrays were 118 
confirmed with Sanger DNA sequencing (Beckman Coulter Genomics) 119 
followed by CRISPR identification using CRISPRfinder.2  120 
Analysis of E. coli by phylogrouping, MLST and plasmid replicon typing 121 
Phylogenetic groups were determined using multiplex PCR according to the 122 
revised method of Clermont et al. 201311 and isolates that were unclassified 123 
according to the method were re-confirmed to be E. coli by MALDI-TOF. 124 
MLST was also performed on Type I-F CRISPR containing isolates using the 125 
7 gene Achtman method.12 O25b-ST131 clones were detected using PCR.13 126 
PCR-based replicon typing was used to screen CRISPR I-F containing E. coli 127 
for the presence of IncF and IncI group plasmids.14  128 
Spacer analysis  129 
CRISPRfinder2 was used to determine the number and sequences of the 130 
spacers within CRISPR3 and CRISPR4 repeat arrays. Nucleotide BLAST and 131 
CRISPRTarget15 were used to search for matching sequences for Type I-F 132 
spacers and a subset of Type I-E spacers. An identity score of 29 was used 133 
as a lower threshold for plasmid matches of interest, excluding matches to 134 
CRISPR regions from other isolates. 135 
RT-PCR for expression analysis 136 
RT-PCR for Type I-F csy1 and cas1 was performed using One Step RT-PCR 137 
kit (Qiagen) using previously described primers (Table 1). The housekeeping 138 
gene rpsL was used as a control. RNA was extracted from bacteria in the 139 
logarithmic phase using an RNeasy minikit (Qiagen) and treated with DNase 140 
using Turbo DNA (Ambion) according to manufacturers’ instructions. Extracts 141 
were confirmed to be devoid of detectable DNA with PCR using the HotStar 142 
Taq kit (Qiagen).  143 
Statistics 144 
Results were analysed using GraphPad Prism 7. A significance level of α: 145 
0.05 was used for all statistics. Fisher’s exact test was used for comparisons 146 
of CRISPR presence between the susceptible and resistant isolates. 147 
 148 
Results and Discussion 149 
All 178 E. coli isolates were screened for four CRISPR arrays (CRISPR 1-4) 150 
found in this species. Overall, over half of the E. coli isolates had at least one 151 
of the screened CRISPR arrays (53.9%) and Type I-E repeat arrays 152 
(CRISPR1 and/or 2) were more common (39.9%) than Type I-F repeats 153 
(CRISPR3 and/or 4) (15.7%). The overall distribution of CRISPR array types 154 
differed significantly between susceptible and MDR groups (P < 0.0001); 155 
CRISPR1 and 2 arrays were overwhelmingly the most prevalent amongst 156 
resistant isolates, whereas in susceptible isolates approximately equal 157 
numbers of both array types (CRISPR1/2 or CRISPR3/4) were found (Figure 158 
1). Type I-E and Type I-F repeats were largely mutually exclusive among the 159 
isolates; only 4 out of the 178 isolates studied had repeats associated with 160 
both CRISPR types, in line with previous findings.5 None of the isolates had 161 
all four repeat arrays. 162 
In addition to screening for the individual repeat arrays, isolates that 163 
were shown to have Type I-F repeats (CRISPR3 and CRISPR4) were also 164 
screened for Type I-F cas genes. Out of the 82 susceptible isolates, 18 165 
(22.0%) had Type I-F systems, defined here as having CRISPR3 and 166 
CRISPR4 as well as the associated genes, and an additional 8 (9.8%) had 167 
only CRISPR3 repeat arrays but without the cas genes. This differs 168 
significantly from the resistant isolates (P < 0.0001) where only two isolates 169 
out of 97 (2.1%) had Type I-F systems and none had CRISPR3 on their own. 170 
Type I-F overrepresentation in susceptible isolates was also demonstrated in 171 
only the Royal Free Hospital subset of isolates collected from the same 172 
hospital and over the same time period (p = 0.0108). 21.2% of the 33 173 
susceptible RFH isolates had CRISPR I-F whereas only 3.5% of the 57 174 
resistant RFH isolates had the system. None of the highly resistant Egyptian 175 
isolates had CRISPR3 or 4. 176 
 There were a total of 65 distinct CRISPR3 spacers and 39 distinct 177 
CRISPR4 spacers with no overlap between the two arrays in terms of spacer 178 
content. Some spacers were common and appeared in multiple non-clonal 179 
isolates, including both susceptible and resistant isolates (Table 2, Figure 2). 180 
Type I-E repeats from 49 susceptible isolates were also sequenced for 181 
comparison. Interestingly, there were 152 and 117 distinct spacers for 182 
CRISPR1 and CRISPR2 respectively, which is greater than the number of 183 
distinct spacers for CRISPR3 and CRISPR4 for the entire group of 178 184 
isolates. However, none of the CRISPR1 and CRISPR2 associated spacers 185 
corresponded to known plasmids and only one corresponded to a known 186 
phage. Most spacers were cryptic with no homology to any known genes. This 187 
is in contrast to the work of Diez-Villasenor et al. who reported a much larger 188 
proportion of spacers with a known origin.16 On the other hand, Nucleotide 189 
BLAST for the Type I-F spacers revealed that five of the spacers matched 190 
conserved regions within IncFII, IncFIB and IncI1 type plasmids with a 191 
minimum of 97% homology (31/32 nucleotides) (Table 2). One spacer 192 
corresponding to klcA, encoding a putative anti-restriction protein, appeared in 193 
20 isolates in total. The klcA gene is conserved among IncI1 and IncFII 194 
plasmid scaffolds, including those associated with the epidemic E. coli ST131; 195 
typified by the CTX-M-15 encoding plasmids pEK516 and pEK499.17, 18 196 
Interestingly, three of the spacers identified (2, 3 and 4 in Table 2) are found 197 
in the same, largely cryptic, region which is shared between IncI1 and IncFII 198 
plasmids. PCR-based screening for plasmid replicons confirmed the absence 199 
of plasmids corresponding to the spacer content of susceptible E. coli isolates 200 
containing Type I-F CRISPR loci. The contrast between the spacer content 201 
between Type I-E and I-F systems supports the hypothesis that the systems 202 
have different functions within E. coli with the Type I-F seemingly being 203 
associated more with plasmids.  204 
Phylogrouping was performed for all 178 isolates and their phylogroup 205 
composition breaks down as follows: A 10.7%, B1 5.6%, B2 55.1%, C 2.3%, 206 
D 14.6%, E 2.8%, F 7.9%, unclassified 1.1%.	The results confirmed a 207 
previously reported16 association between CRISPR subtype and phylogenetic 208 
groups. CRISPR I-F systems were only found in B2 group isolates whereas I-209 
E systems never appeared in B2 isolates. However, lone CRISPR3 arrays 210 
without cas genes or CRISPR4 were detected in phylogroups A, D, E and F 211 
(Table S1). Our results show that B2 isolates are more common in the 212 
susceptible group (65.4%) than in the resistant group (49.0%). Since Type I-F 213 
systems only appear in the B2 group, we analysed Type I-F presence within 214 
the B2 group only and found a significant difference between susceptible and 215 
MDR resistant isolates within B2 (p = 0.0001) (Figure 3). Further, MLST 216 
analysis was performed on all isolates with Type I-F systems as well as 10 217 
randomly selected susceptible isolates without Type I-F CRISPR. All isolates 218 
underwent PCR screening for the O25b-ST131 epidemic clone.13 The MLST 219 
types of Type I-F positive isolates suggested clustering within particular STs, 220 
with nine of the 20 isolates with Type I-F systems belonging to the ST95 221 
clonal complex, including one of the resistant isolates with Type I-F systems. 222 
The second most common sequence type among Type I-F isolates was 223 
ST141 (3/20). Plasmid-corresponding spacers were largely limited to these 224 
two sequence types (Figure 2). The MLST types of isolates without I-F 225 
CRISPR systems were representative of urinary E. coli found in other studies 226 
(Table S1).19 227 
A previous study found that unlike the Type I-E system, Type I-F genes 228 
can be expressed under laboratory conditions.9 We therefore used RT-PCR to 229 
investigate the expression of the csy1 and cas1 genes at the log phase of 230 
growth in 7 Type I-F isolates (6 from the susceptible group and 1 from the 231 
MDR group). These two genes are the first in the two putative transcriptional 232 
units of the Type I-F cas genes.9 In all seven of the Type I-F strains tested, 233 
both transcriptional units were expressed in the log phase of growth. 234 
 In this work we show that the presence of the Type I-F CRISPR 235 
systems is strongly associated with antimicrobial susceptibility in E. coli. 236 
Reinforcing previous research,5, 16 we also demonstrate that Type I-F systems 237 
are only typically associated with the B2 phylogenetic group. However, our 238 
results are in contrast to a previous study, which did not show an association 239 
between the distribution of CRISPR and antimicrobial resistance plasmids in 240 
E. coli.20 When only considering the B2 group, which is the only group that 241 
can contain Type I-F genes, the presence of Type I-F system is still strongly 242 
associated with antimicrobial susceptibility. We also show that Type I-F genes 243 
are expressed in a number of clinical isolates of E. coli and therefore 244 
theoretically capable of interfering with antimicrobial resistance plasmids. 245 
Indeed, a study by Almendros et al. demonstrated that an isolate with an 246 
expressed Type I-F system was also capable of interfering with plasmid 247 
constructs containing matching spacers.9 248 
Previous work has shown that some B2 lineages such as ST131 are 249 
associated with antimicrobial resistance.21, 22 None of the ST131 isolates 250 
included within our study contained Type I-F systems. What was more striking 251 
was the finding that CRISPR3 and CRISPR4 arrays incorporated spacer 252 
sequences derived from IncFII and IncI1 plasmid scaffolds commonly linked 253 
to resistant E. coli clones such as ST131. ST95 strains are often 254 
underrepresented in resistant groups of E. coli23, 24 and our data suggest that 255 
CRISPR may be a contributing factor, given that 9/20 of the Type I-F positive 256 
isolates reported here belonged to the ST95 clonal complex. We suggest that 257 
B2 strains with active Type I-F CRISPR systems may be interfering with the 258 
uptake or survival of antimicrobial resistance plasmids within the isolate, 259 
hence helping to keep them susceptible to antimicrobials.  260 
 The observation that some of these spacers still persist in multiple 261 
isolates and different sequence types may be an indication that they are 262 
advantageous, particularly since the spacers can correspond to more than 263 
one plasmid. In environments where antimicrobials are scarce or absent, 264 
plasmids may confer a fitness cost,25 and in these conditions, B2 strains with 265 
Type I-F systems may have an advantage. While we did find two MDR 266 
isolates with Type I-F spacers that correspond to antimicrobial resistant 267 
plasmids, this could be explained by the fact that CRISPR systems have been 268 
shown to have leakage and are not functionally perfect even with exact 269 
spacer matches and optimal PAMs.9, 26 There is also the possibility that the 270 
system has been deactivated as reported in Staphylococcus epidermis.25  271 
Taken together our findings suggest a role for Type I-F CRISPR in the 272 
distribution of antimicrobial resistance among E. coli B2 lineages.  273 
 274 
Acknowledgements 275 
We would like to thank staff at the Royal Free Hospital Microbiology 276 
laboratory for their assistance with collecting recent clinical isolates. We would 277 
also like to thank Prof Barry Cookson for initial discussions. 278 
Also, we are grateful to the US. Naval Medical Research Unit-3 (US. NAMRU-279 
3), and the Centers for Disease Control and Prevention (CDC) partnership 280 
Global Disease Detection and Response Program (GDDRP) for supplying the 281 
Egyptian E. coli isolates (as part of Enas Newire’s PhD), and partly supporting 282 
in their basic phenotypic testing. 283 
Funding 284 
Enas Newire is supported by the Schlumberger Foundation’s Faculty for the 285 
Future Program. No specific funding was received for this work. 286 
Transparency declarations 287 
None to declare. 288 
 289 
References 290 
1. Marraffini LA, Sontheimer EJ. CRISPR interference: RNA-directed 291 
adaptive immunity in bacteria and archaea. Nat Rev Genet 2010; 11: 181-90. 292 
2. Grissa I, Vergnaud G, Pourcel C. The CRISPRdb database and tools 293 
to display CRISPRs and to generate dictionaries of spacers and repeats. 294 
BMC Bioinform 2007; 8: 172. 295 
3. Horvath P, Barrangou R. CRISPR/Cas, the immune system of bacteria 296 
and archaea. Science 2010; 327: 167-70. 297 
4. Louwen R, Staals RH, Endtz HP et al. The role of CRISPR-Cas 298 
systems in virulence of pathogenic bacteria. Microbiol Mol Biol Rev 2014; 78: 299 
74-88. 300 
5. Touchon M, Charpentier S, Clermont O et al. CRISPR distribution 301 
within the Escherichia coli species is not suggestive of immunity-associated 302 
diversifying selection. J Bacteriol 2011; 193: 2460-7. 303 
6. Touchon M, Rocha EP. The small, slow and specialized CRISPR and 304 
anti-CRISPR of Escherichia and Salmonella. PloS One 2010; 5: e11126. 305 
7. Makarova KS, Wolf YI, Alkhnbashi OS et al. An updated evolutionary 306 
classification of CRISPR-Cas systems. Nat Rev Microbiol 2015; 13: 722-36. 307 
8. Westra ER, Pul U, Heidrich N et al. H-NS-mediated repression of 308 
CRISPR-based immunity in Escherichia coli K12 can be relieved by the 309 
transcription activator LeuO. Mol Microbiol 2010; 77: 1380-93. 310 
9. Almendros C, Guzman NM, Diez-Villasenor C et al. Target motifs 311 
affecting natural immunity by a constitutive CRISPR-Cas system in 312 
Escherichia coli. PloS One 2012; 7: e50797. 313 
10. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, 314 
extensively drug-resistant and pandrug-resistant bacteria: an international 315 
expert proposal for intern standard definitions for acquired resistance. Clinical 316 
Microbiol Infect 2012; 18: 268-81 317 
11. Clermont O, Christenson JK, Denamur E et al. The Clermont 318 
Escherichia coli phylo-typing method revisited: improvement of specificity and 319 
detection of new phylo-groups. Environ Microbiol Rep 2013; 5: 58-65. 320 
12. Wirth T, Falush D, Lan R et al. Sex and virulence in Escherichia coli: 321 
an evolutionary perspective. Mol Microbiol 2006; 60: 1136-51. 322 
13. Clermont O, Dhanji H, Upton M et al. Rapid detection of the O25b-323 
ST131 clone of Escherichia coli encompassing the CTX-M-15-producing 324 
strains. J Antimicrob Chemother 2009; 64: 274-7. 325 
14. Carattoli A, Bertini A, Villa L et al. Identification of plasmids by PCR-326 
based replicon typing. J Microbiol Meth 2005; 63: 219-28. 327 
15. Biswas A, Gagnon JN, Brouns SJ et al. CRISPRTarget: Bioinformatic 328 
prediction and analysis of crRNA targets. RNA Biol 2013; 10: 817-827 329 
16. D Díez-Villaseñor C,  Almendros C,  García-Martínez J et al. Diversity 330 
of CRISPR loci in Escherichia coli. Microbiol 2010; 156: 1351-1361 331 
17. Enne VI, Delsol AA, Roe JM et al. Evidence of antibiotic resistance 332 
gene silencing in Escherichia coli. Antimicrob Agents Chemother 2006; 50: 333 
3003-10. 334 
18. Woodford N, Carattoli A, Karisik E et al. Complete nucleotide 335 
sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M 336 
enzymes in three major Escherichia coli lineages from the United Kingdom, all 337 
belonging to the international O25:H4-ST131 clone. Antimicrob Agents 338 
Chemother 2009; 53: 4472-82. 339 
19. Riley LW. Pandemic lineages of extraintestinal pathogenic Escherichia 340 
coli. Clin Microbiol Infect 2014; 20: 380-390. 341 
20. Touchon M, Charpentier S, Pognard D et al. Antibiotic resistance 342 
plasmids spread among natural isolated Escherichia coli in spite of CRISPR 343 
elements. Microbiology 2012; 158: 2997-3004. 344 
21. Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance 345 
plasmids and international high-risk clones in the spread of multidrug-resistant 346 
Enterobacteriaceae. Clin Microbiol Rev 2015; 28: 565-91. 347 
22. Adams-Sapper S, Diep BA, Perdreau-Remington F et al. Clonal 348 
composition and community clustering of drug-susceptible and -resistant 349 
Escherichia coli isolates from bloodstream infections. Antimicrob Agents 350 
Chemother 2013; 57: 490-7. 351 
23. Bengtsson S, Naseer U, Sundsfjord A et al. Sequence types and 352 
plasmid carriage of uropathogenic Escherichia coli devoid of phenotypically 353 
detectable resistance. J Antimicrob Chemother 2012; 67: 69-73. 354 
24. Golding GR, Persaud N, Levett PN et al. Characterization of 355 
Escherichia coli urinary tract infection isolates in remote northern 356 
Saskatchewan communities: the Northern Antibiotic Resistance Partnership. 357 
Diagn Microbiol Infect Dis 2012; 74: 242-7. 358 
25. Vogwill T, MacLean RC. The genetic basis of the fitness costs of 359 
antimicrobial resistance: a meta-analysis approach. Evol Appl 2015; 8: 284-360 
95. 361 
26. Jiang W, Maniv I, Arain F et al. Dealing with the evolutionary downside 362 
of CRISPR immunity: bacteria and beneficial plasmids. PLoS Genet 2013; 9: 363 
e1003844. 364 
  365 
Tables 366 
 367 
Name Sequence (5’ to 3’) Purpose Source 
C1 fw GTTATGCGGATAATGCTACC CRISPR 
screening 
5 
C1 rev CGTAYYCCGGTRGATTTGAA 
C2 fw AAATCGTATGAAGTGATGCAT CRISPR 
screening 
5 
C2 g rev TCGATAATTGTGAACYTMTC 
C3 fw GCGCTGGATAAAGAGAAAAAT CRISPR 
screening 
5 
C3 rev GCCCACCATTCACCTGTA 
C4 fw CTGAACAGCGGACTGATTTA CRISPR 
screening 
5 
C4 rev GTACGACCTGAGCAAAG 
Csy1 fw TCAGTCATGGTGATTCT cas gene 
screening 
& RT-PCR 
9 
Csy1 rev GCAACAGGGAAATAGA 
Cas1 fw CGGGGTGATGGTAGGCTTTT cas gene 
screening 
& RT-PCR 
This 
study Cas1 rev TGGTTTTCTGCCGCGTCTAT 
RPSL fw CTCGCAAAGTTGCGAAAAGC RT-PCR 
control 
17 
RPSL rev TTCACGCCATACTTGGAACG 
 368 
Table 1.  Oligonucleotides used for CRISPR screening and gene expression 369 
studies. Oligonucleotides used for phylogenetic grouping, MLST and plasmid 370 
replicon typing are primers not included. 371 
  372 
Name 
of 
spacer 
CRISPR 
array Sequence (5’ to 3’) 
No. of 
isolates 
Protospacer 
match  
Spacer1 CRISPR3 AGCATCTGCATGGTGCCCGTGGTCTTAACAAG  1 
IncFII/FIB 
plasmids 
Spacer2 CRISPR3 TGATGGCGCAGCAGTCCTCCCTCCTGCCGCCA 13 
Non-coding region 
of IncI1 and IncFII 
plasmids 
Spacer3 CRISPR3 CTGAACGTTGAAGAGTGCGACCGTCTCTCCTT 20 
Putative anti-
restriction protein 
KlcA on IncI1 and 
IncFII plasmids 
Spacer4 CRISPR3 GGAAGAGACGGATGTTGACCAGCGAAATCCGA 1 
Hypothetical 
protein found on 
IncFII and IncI1 
plasmids 
Spacer5 CRISPR4 TGTGGCGCTGATGCGTCTGGGCGTCTTTGTAC 8 
repA gene of 
IncFIB plasmids 
 373 
Table 2. Spacer sequences matching antimicrobial resistance plasmids. Five 374 
spacers that correspond to plasmid sequences were found using nucleotide 375 
BLAST in CRISPR3 and CRISPR4 containing strains, including isolates which 376 
had repeat arrays but no I-F genes. 377 
  378 
  379 
Figures 380 
	  381 
Figure 1. Proportion of E. coli isolates with CRISPR 1, 2, 3 and 4 repeat 382 
arrays within the susceptible and MDR groups. Overall the two groups had a 383 
significantly different distribution of CRISPR arrays (P < 0.0001). CRISPR 1 & 384 
2 and CRISPR 3 & 4 are often, but not always, found in pairs.  385 
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Figure 2. CRISPR3 and CRISPR4 array profiles found in isolates containing 389 
Type I-F genes. Each box represents a spacer sequence. Isolates of the 390 
same sequence type have similar spacer profiles but often with missing or 391 
additional spacers. Shaded spacers correspond to known antimicrobial 392 
resistance plasmids listed in Table 2. MLST types of all isolates with complete 393 
Type I-F systems are listed 394 
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Figure 3. Presence of Type I-F systems in susceptible and resistant B2 397 
isolates. ‘Type I-F systems’ are defined here as presence of both Type I-F 398 
repeat arrays and cas genes. 399 
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